Although the ongoing sea change in healthcare is primarily related to delivery, every industry within the sector is affected. Reducing costs and time-to-market is particularly crucial in drug development where new chemical entity discovery has traditionally been hit and miss, and where big pharma has wasted billions in R&D dollars. The companies have as much admitted the inefficiencies of their own R&D and development by linking themselves strategically with CROs.
We believe this provides an opportunity for companies who can effectively fill the drug discovery and development gap by reducing time to discovery of useful molecules, in addition to predicting the activity of molecules in vivo in order to reduce the time and cost of clinical trials and of the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|